This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
by Santanu Roy
Our time-tested methodologies helped investors navigate the market well last week. Here are some of our key performance data from the past three months.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
by Zacks Equity Research
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
by Zacks Equity Research
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with developing its lead investigational pipeline candidate, certepetide, which is being studied for various cancer indications.
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
by Zacks Equity Research
Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.
All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy
by Zacks Equity Research
Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.
Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study
by Zacks Equity Research
Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.
Beat the Market Like Zacks: NVIDIA, VirTra, Rockwell Medical in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Take the Zacks Approach to Beat the Market: NVIDIA, Lisata, Shopify in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy
by Zacks Equity Research
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.
Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug
by Zacks Equity Research
The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.
Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence
by Zacks Equity Research
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.
4 Medical Stocks to Buy as Rate Hike Cycle Nears End
by Indrajit Bandyopadhyay
We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.